A precious metal which has never before been used in a clinical setting is being developed as an anti-cancer agent by University of Warwick researchers. The metal, osmium, is closely related to platinum, which is widely used to treat cancers in the form of the drug cisplatin. Most famously, the cyclist Lance Armstrong was treated with cisplatin for testicular cancer.
Now the researchers, based in the Department of Chemistry, at the University of Warwick, are working closely with Warwick Ventures, the university’s technology transfer office, to seek partners to help develop the potential of osmium through more extensive biological tests. The team will be presenting their work on 9 December at the national university technology showcase event, Bioversity.
Professor Peter Sadler, of the Department of Chemistry, explained: "Although cisplatin has been proven to be a very successful treatment; it is not useful for all kinds of cancer. It is also quite a toxic therapy, which can produce side effects and, from a clinical point of view, cells can also become resistant to platinum."
Osmium, with its special chemical properties, offers a new potential solution to an unmet clinical need. It has shown huge promise in treating several different types of cancer cell, including ovarian and colon cancers which have been developed and tested in the laboratory. The metal also has another advantage in that it is a much cheaper alternative to platinum.
Professor Sadler, along with post-graduate researcher Sabine van Rijt, is working to develop new compounds using Osmium, which they hope will lead to the development of drugs which could be used in combination therapies alongside existing drugs such as cisplatin.
"The compounds we have been developing are very promising," says Sabine van Rijt. "We’re building a picture of how different compounds might interact with DNA in cancer cells. By making changes to the coating, or ligand, on the metal, we can also affect not just how it interacts, but the rate of interaction.
During this design process we can also make changes which can control the activity of the compound."
She added: "Another advantage is that these compounds are not cross-resistant with platinum. They kill the cancerous cells in a different way, so they could be used alongside platinum in combination therapies."
The team’s research is being presented on 9 December at Bioversity 2008, a national university technology showcase event. Bioversity is part of the biotechnology conference, Genesis 2008, organised by The London Biotechnology Network.
For media enquiries, please contact:
Peter Dunn, Press and Media Relations Manager, University of Warwick.
Tel: 024 76 523708 or 07767 655860; email: email@example.com
Beck Lockwood, Campuspr Midlands Ltd. Tel: 0121 451 1321; mobile: 0778 3802318; email: firstname.lastname@example.org
Notes for editors:
1. Warwick Ventures was created in April 2000 to build on the research successes of the University of Warwick. Warwick Ventures is responsible for ensuring that the intellectual property that is the result of the University's annual research spend – some £86 million - is properly protected and commercialised for the benefit of the academics, the University, the region and the nation. For more information, see: www.ventures.warwick.ac.uk